logo

For the Inventor, By the Inventor

Newton, MA, United States of America

David Kenneth Gifford

USPTO Granted Patents = 14 

Average Co-Inventor Count = 2.0

ph-index = 5

Forward Citations = 41(Granted Patents)


Company Filing History:

goldMedal14 out of 14 
 
Think Therapeutics, Inc.
 patents

Years Active: 2021-2025

Loading Chart...
14 patents (USPTO):Explore Patents
1. 12486501 - Multiplexed testing of lymphocytes for antigen specificity (2025-12-02),
2. 12364741 - Immunogenic compositions comprising nucleic acids for RAS peptides and their use for treating cancer (2025-07-22),
3. 12290554 - Compositions for optimized BCR-ABL peptide vaccines (2025-05-06),
4. 12091443 - Method of compact peptide vaccines using residue optimization (2024-09-17),
5. 12064475 - Compositions and method for optimized peptide vaccines using residue optimization (2024-08-20),
6. 11673936 - Method of compact peptide vaccines using residue optimization (2023-06-13),
7. 11672850 - Compositions and method for optimized peptide vaccines using residue optimization (2023-06-13),
8. 11464842 - Compositions and method for optimized peptide vaccines using residue optimization (2022-10-11),
9. 11464837 - Immunogenic compositions comprising nucleic acids for RAS peptides (2022-10-11),
10. 11421015 - Method of compact peptide vaccines using residue optimization (2022-08-23),
11. 11235039 - Immunogenic compositions comprising nucleic acids for RAS peptides (2022-02-01),
12. 11161892 - Method of compact peptide vaccines using residue optimization (2021-11-02),
13. 11111489 - Multiplexed testing of lymphocytes for antigen specificity (2021-09-07),
14. 11058751 - Compositions for optimized RAS peptide vaccines (2021-07-13),

Title: David Kenneth Gifford: Innovator in Cancer Treatment

Introduction

David Kenneth Gifford is a prominent inventor based in Newton, MA, known for his significant contributions to the field of cancer treatment. With a total of 13 patents to his name, Gifford has been at the forefront of developing innovative immunogenic compositions that utilize nucleic acids and peptides.

Latest Patents

Gifford's latest patents include groundbreaking work on immunogenic compositions comprising nucleic acids for RAS peptides, aimed at treating cancer. This patent outlines methods, systems, and compositions that involve nucleic acid sequences encoding various amino acid sequences. Additionally, he has developed immunogenic peptide compositions that consist of multiple peptides selected from a comprehensive list of sequences. Another notable patent focuses on optimized BCR-ABL peptide vaccines, providing methods and compositions that enhance the efficacy of cancer treatments.

Career Highlights

Throughout his career, Gifford has made substantial advancements in the field of biotechnology. His work has not only contributed to the scientific community but has also paved the way for new therapeutic approaches in oncology. He is currently associated with Think Therapeutics, Inc., where he continues to innovate and develop new solutions for cancer treatment.

Collaborations

Gifford collaborates with various professionals in the field, including his coworker Brandon Carter, to further enhance the impact of his inventions. Their combined expertise fosters a creative environment that drives the development of effective cancer therapies.

Conclusion

David Kenneth Gifford's innovative work in cancer treatment through his patents and collaborations highlights his commitment to advancing medical science. His contributions are paving the way for new therapeutic options that could significantly improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…